Family Medicine Innovation Medical Specialties Pharma & Biotechnology Press

Pfizer aims for 10-20 million doses of coronavirus vaccine by end-2020

Pfizer aims to make 10-20 million doses of a coronavirus vaccine it is developing with Germany’s BioNtech by the end of 2020 for emergency use should it pass tests, the U.S. drugmaker’s head of vaccines said on Thursday.

The companies, whose project relies on messenger RNA technology never before used in an approved vaccine, have dosed the first humans in Germany and hope to begin a U.S. trial soon, pending regulators’ blessing.

Pfizer, BioNtech and other companies are racing to develop a vaccine, since there are currently no approved treatments and only mixed results of medicines under study against the virus.

Britain’s AstraZeneca said on Thursday it had joined with the University of Oxford on a vaccine project also being tested in volunteers.

Making millions of doses within just months, as Pfizer hopes, would mark almost unprecedented speed and require swift regulatory action.

“Of course we need to see and wait to see how the vaccine’s efficacy and safety is demonstrated, hopefully in the coming months,” Nanette Cocero, global head of Pfizer Vaccines, said on a call organised by Geneva-based industry group International Federation of Pharmaceutical Manufacturers (IFPMA).

“Assuming that is demonstrated, we are looking to ramp up manufacturing rather quickly to have around 10 to 20 million doses by the end of this year, which are expected to then of course be used in an emergency type of setting.”

Other drugmakers testing more than 70 COVID-19 vaccine candidates include Moderna, Johnson & Johnson and Novavax, and smaller projects like at Bern’s Inselspital hospital in Switzerland.

Read More

Meeta Ramnani
Meeta Ramnani
Meeta develops credible content about various markets based on deep research, opinions from experts and inputs from industry leaders. As the managing editor at Smart Industry News, she assures that every piece of news and article adds to the knowledge of decision makers. An avid bike rider, Meeta, is a postgraduate from Indian Institute of Journalism and New Media (IIJNM) Bangalore, where her specialization was Business Journalism. She carries experience from mainstream print media including The Times Group and Sakal Media Group.
https://smarthealthcarenews.com/